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The activity of endocrine-active agents exhibits specificity at many levels. Differential responsiveness
to these agents has been observed between different species and extends to interindividual
differences within a species and between different tissues as well. In cases where they have been
identified, the biologic and molecular mechanisms underlying this specificity are quite diverse.
Determinants of species specificity include differences that exist in receptor binding, gene
transcription, and cellular responses to endocrine-active compounds between species. Interindividual
differences in responsiveness may be determined at the level of genetic polymorphisms in hormone-
metabolizing enzymes, hormone receptors, and in those genes that are transactivated by these
receptors, as well as during changing windows of susceptibility that occur as a function of age, such
as prenatal and postmenopausal exposures. Extrinsic factors such as diet can also impact individual
susceptibility to endocrine-active agents. Tissue-specific determinants of susceptibility are well
documented, but little is known regarding the mechanisms underlying these different responses.
Differences in the expression of accessory proteins for steroid hormone receptors and different
patterns of receptor expression, estrogen receptor a and estrogen receptor ,B for example, may
contribute to tissue specificity, as may differences in the pattern of expression of other genes such
as hormone-metabolizing enzymes. The use of animal model systems and development of
appropriate mathematical models has the potential to yield additional valuable information for
elucidating the role of these determinants of specificity at low-dose exposures and for improved risk
assessments for the adverse health effects of endocrine-active compounds. Key words: animal
models, endocrine disruptor, metabolizing enzymes, p450, polymorphisms, reproductive tract, steroid
hormone receptors, susceptibility. - Environ Health Perspect 107(suppl 4):619-624 (1999).
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This article is the result of a workshop
concerned with characterizing the effects of
endocrine disruptors on human health at
environmental exposures. This workshop pro-
vided a forum for the discussion ofmethods
and data needed to improve risk assessments
ofendocrine disruptors. This working group
report addresses issues related to the physio-
logic and biochemical basis for species,
interindividual, and tissue-specific differences
in response to an endocrine-disrupting chemi-
cal at environmentally relevant doses. In these
discussions, group members addressed what
factors have been identified that may underlie
differential responsiveness at each of these
levels and where questions remain to be
answered regarding the basis for differences in
response that should serve to direct future
research initiatives. Included in this report are
issues related to genetic versus epigenetic phe-
nomena, the adequacy of in vitro and in vivo
models for predicting variability, and how this
bodyofinformation could be used to improve
risk assessments for sensitivesubpopulations.
Species-Specific Factors That
Can Impact Endocrine
Signaling
Three levels of hormone activity at which
species-specific factors may have an impact
were discussed: receptor binding, gene
transcription, and cellular response.
Recptor Binding
Several factors were identified that can affect
receptor binding to endogenous and poten-
tiallyexogenous hormonally active compounds
(1,2). Such factors includeserum-binding pro-
teins (SBPs) that sequester and/or transport
hormones to target cells. SBPs are differentially
expressed in different species. Although in
humans, steroid hormones are found primarily
associated with SBPs in the blood, the rat does
not express this protein. Both rats and humans
express a-fetoprotein during fetal develop-
ment, but this expression does not persist in
the adult rat. SBPs increase/activate cyclic
adenosine monophosphate (cAMP) when
bound to steroid hormones in hormonallysen-
sitive cells such as the prostate (3,4). Because
endocrine disruptors exhibit differences in
their ability to bind these same proteins, it
would be important to assess whether they
may similarly initiate this activation cascade
and at what doses.
Differences also exist in the ligand-
binding domain ofsteroid hormone receptors
from different species. Whereas rodent and
human estrogen receptors (ER) are essentially
the same, fish and quail receptors exhibit
significant variation in their ligand-binding
domains compared to humans. In fact, in
some species, receptors are adapted to recog-
nize different hormones (for example, trout
androgens and their cognate receptor).
However, receptors from all species appear
to recognize the same consensus sequence in
the DNA.
Ligand-independent receptor activation
also exhibits species specificity (5,6). Ligand-
independent progesterone receptor (PR) acti-
vation does not occur in humans but has
been observed for rodents and chickens. The
androgen receptor (AR) appears to exhibit
ligand-independent activation in humans but
not in rats (7). However, whether this differ-
ence is real or due to interlaboratory experi-
mental variation is unclear. Similar species
differences could also exist at the level ofrecep-
tor crosstalk, cAMP activation, and AP1
signaling (nontraditional promoter events),
and as these differences could impact on the
activity ofendocrine disruptors in different
species, this area warrants further exploration.
In particular, ligand-independent activation is
facilitated by low levels ofhormones ("prim-
ing the pump"), suggesting that these non-
traditional means of receptor activation may
beparticularly relevant forlow-dose exposures.
GeneTransription
In terms ofspecific gene transcription, the
work group identified a need to assess the
available literature on gene transcription in
different species in response to steroid hor-
mones. This discussion led further to a con-
sensus that a hormone-responsive gene chip
would be very useful for making this assess-
ment. Such a chip, containing a battery of
hormone-responsive genes, could be used to
quantitate changes in the expression ofthese
genes in different species in response to
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endogenous and exogenous hormones in
human, rat, mouse, and fish (fathead min-
now). Patterns ofgene expression could then
be compared across multiple species to iden-
tify similarities and differences in hormonally
regulated gene expression that could be later
correlated with species-specific responses.
CelularResponse
Differences in hormone responses have been
observed between different species in several
hormone-responsive tissues that may be rele-
vant to low-dose effects. In the rat, the devel-
opment of mammary gland tumors is
enhanced by pituitary prolactin production.
For example, estradiol-induced tumors in
AxC and Noble rats can be inhibited by
hypo. In contrast, secretion ofpituitary pro-
lactin is not required for tumorigenesis in
humans but may in fact be compensated for
by theendogenous production ofprolactin by
the tumors themselves. Thus, as a target for
endocrine-disrupting chemicals, altered pitu-
itary function may have quite a different
impact in rats than inhumans.
Other species differences exist in the
timing ofwindows ofsusceptibility to the
effects ofendocrine-disrupting chemicals.
For example, in the mouse a critical window
for estrogen exposure in terms ofchanges in
prostate weight occurs prenatally, whereas in
the rat, postnatal exposures have the most
dramatic effects on the prostate. Treatment
ofrats on postnatal day 3 with either diethyl-
stilbestrol (DES) or estradiol produces a
decrease in prostate size and increased dys-
plasia and carcinoma development in the
mature prostate gland.
The existence of the species-specific
differences described above underscores the
fact that mechanistic information will be nec-
essary to make informed choices regarding
the appropriateness ofa given animal model
for modeling and testing ofadverse human
health effects as a result of exposure to
endocrine disruptors.
Intrinsic/Genetic Factors
Responsiblefor Interindividual
Difflerences
Individuals may exhibit differences in
susceptibility to endocrine disruptors during
different stages oftheir life cycle relative to
adult exposures, and this information should
be factored into human risk assessments.
Different susceptibilities may exist for pre-
natal, postnatal, peripubertal, adult, and aged
subpopulations (8,9). Prenatally, uterine
position effects that have been documented
for rodents suggest that very low levels of
androgens, and byinference endocrine disrup-
tors, may have effects on the organization of
neural and other tissues and may have perma-
nent masculinizing consequences. Variability
in anatomical, physiologic and behavioral
characteristics ofmouse, rat, and gerbil as a
consequence offetal androgen exposure has
also been observed. A window ofsusceptibil-
ity has been documented for postnatal expo-
sures to polychlorinated biphenyls (PCBs)
and mercury in terms ofbehavioral/neuro-
logic effects in humans. Experiencewith DES
exposures in both humans and rodents indi-
cates that similar windows ofsusceptibility
exist for the induction ofreproductive tract
abnormalities and cancer during pre- and
postnatal periods ofdevelopment. The pro-
gressive decrease in age of menarche in
women that has occurred over previous
decades may result in an increased time until
first pregnancy ifmaternal age at conception
remains the same. This population shift
toward early menarche-late pregnancy could
result in an increase in breast cancer risk
within the population. This same change
however, could also prove protective for other
endocrine-related processes such as osteo-
porosis. In aged populations, decreased repair
enzyme function due to oxidative inactivation
decreased detoxification capability, and
changes in endogenous hormone levels or
metabolites may place this subpopulation at
increased risk for the adverse health effects of
endocrine disruptors.
Along these same lines, issues were raised
in the work group related to cyclical versus
persistent exposures. All steroids are released
in a rhythmic fashion and some receptor sys-
tems show rhythmic changes. It is thus possi-
ble that low-dose effects could occur ifthey
are persistent in a system in which endoge-
nous hormone levels exhibit peaks andvalleys.
Although the amount ofendocrine disruptor
present might be low relative to peak hor-
mone levels, it could have a biologic impact if
exposure occurs during a time in which
endogenous hormones themselves are at very
low levels or ifthe exposure to an endocrine
disruptor occurs at asusceptible period during
cyclical changes in hormone levels. In a simi-
lar vein, an interesting question was raised
regarding circadian rhythms and whether
there were any data to suggest that hormones
could have different effects as a function of
these rhythms. It was noted that there is an
evolutionary link between transcription fac-
tors associated with dioxin activity (an
endocrine-disrupting compound) and factors
involved in regulatingcircadian rhythms.
The question that arises as a natural
consideration ofthesedataishowmuch more
susceptible might individuals be during these
different life stages? Additional analysis of
availabledata maygive some indication ofthe
magnitude ofthis increased susceptibility,
much as earlier analyses for dioxin (in which
good quantitation for species and age effects
was available) helped quantify dose-response
effects for this compound. However, this is
clearly one area in which additional research
will be necessary to understandwhich adverse
health effects resulting from exposure to
endocrine disruptors occur as quantitative
alterations in different susceptible subpopu-
lations and which effects are qualitative
in nature and specific for a given window
ofexposure.
Polymorphisms in steroid hormone-
metabolizing genes also represent genetic fac-
tors that can predispose to adverse health
effects ofendocrine disruptors (10-12). 5ac-
Reductase levels can be alteredbythe presence
ofTA dinudeotide repeats in the 3' region of
the gene and changes in these levels can
impact the conversion oftestosterone to dihy-
drotestosterone (DHT), the active form of
thishormone. Thesepolymorphisms have also
been linked to increased riskofprostatic carci-
noma, although this is somewhat controversial
(13-15). The V89L substitution can also
affect 5a-reductase activity. Polymorphisms in
several cytochrome P450 genes, including
CyplB1 and Cypl7a (aromatase) as well as
catechol-OH-transferase (COMT), have
been linked to increased risk ofhormone-
dependent cancers including breast cancer.
Similarly, deletions in glutathione transferase,
a detoxifying enzyme for xenobiotics that is
present in some individuals, put them at
increased risk for breast and prostate cancer,
possibly as a result ofincreased endogenous/
exogenous hormonelevels (16).
Receptor polymorphisms may also
increase susceptibility to endocrine disruptors
via changes in the regulation or function of
steroid hormone receptors (10). AR hyper-
sensitivity is a function of the length of
CAG nucleotide repeats, with individuals
carrying shorter length repeats expressing
AR that are more sensitive to androgens
(17). Polymorphisms in the PR have been
associated with increased risk for ovarian
cancer, possibly due to increased activity or
stability ofthe receptor. Similar polymor-
phisms mayexistforER-a andER-p.
Target gene polymorphisms can also
predispose to hormonally related diseases
such as breast cancer (18). Individuals carry-
ing BRCA1 mutations, for example, are
refractory to the protective effects ofpreg-
nancy on breast cancer risk. Whether such
target gene mutations would predispose indi-
viduals to the adverse health effects of
endocrine disruptors is not known at this
time. Mutations in other potential target
genes mayalso soon be identified through the
Environmental Genome Project, and these
will need to be investigated to determine if
they can potentially affect susceptibility to
low-dose exposures.
Several of the genetic alterations and
polymorphisms noted above may contribute
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to the observed ethnic differences in risk for
hormonally related diseases such as breast
cancer and prostate cancer. The frequency of
higher activity alleles ofCyplB1 that result in
increased 4-OH-estradiol (4-OH-E2) levels,
which in turn are associated with increased
potential for free radical damage to the DNA
and more potent activation of the ER than
17[-estradiol (17BE2), are more prevalent in
African Americans than Caucasians and may
contribute to increased breast cancer risk
(19). Similarly, alleles of COMT with
decreased activity could also increase 4-OH-
E2 levels and increase risk for developing
postmenopausal breast cancer (11). There is
evidence that endocrine disruptors can modu-
late the activity ofestradiol-metabolizing
enzymes, with indole-3-carbinol increasing
the extent of2-hydroxylation ofestradiol and
decreasing mammary tumor incidence and
multiplicity in mice (20), whereas PCBs can
increase the production of 16a-OH metabo-
lites ofestrogen that can bind to the ER and
form a protein-reactive Schiffbase. The ratio
of2-OH to 16a-OH metabolites is thought
to be one determinant ofbreast cancer risk,
with compounds that shift the balance
toward 2-OH being protective and those that
produce increases in 16a-OH increasing
cancer risk.
Several research needs were identified as a
result ofthese discussions related to possible
genetic determinants ofsusceptibility. First,
many ofthe studies relating genetic polymor-
phisms in the population to increased risk for
a particular disease are quite controversial
and conflicting data sets have been reported.
Therefore, a primary research need is to con-
firm these studies and resolve conflicting data
present in the literature. Second, the impact
ofreceptor polymorphisms on receptor acti-
vation by endocrine disruptors should be
investigated to determine if any of these
polymorphisms may predispose individuals
to the adverse health effects ofthese chemi-
cals. Finally, the functionality of genetic
polymorphisms in metabolizing genes or
other relevant genes, especially in terms of
how they affect the dose-response curves
for endogenous or exogenous compounds
resulting in shifts in sensitivity or response
levels, needs to be determined.
A second area ofresearch needs relates to
epigenetic effects on responsivity to endocrine
disruptors. Hormonal exposure early in devel-
opment has organizational and lasting effects
on later sensitivity to hormones that activate
hormone-dependent physiologic and behav-
ioral functions. For example, it would be
important to learn whether exposure of a
fetus to one or more natural or xenobiotic
endocrine-active substances has long-term
effects on susceptibility, i.e., endocrine
imprinting (10,12,21).
Extrinsic Factors Affecting
Susceptibility
Several extrinsic factors such as diet,
socioeconomic status, and obesity affect the
risk for hormonally related diseases such as
breast cancer. Dietary history and previous
chemical exposures can produce a biologic
imprint that can persist even in the absence of
the continued presence ofthe causative agent.
These types ofhistorical exposures may be
very difficult to assess in human populations
but must be considered as important con-
tributing risk factors. Obesity can have dra-
matic affects on the hormonal milieu,
especially in postmenopausal women in which
aromatization offat stores can significantly
alter estrogen levels, particularly levels of
estriol and estrone. Similarly, increasedweight
gain in adolescent girls appears to be one of
the contributing factors to early onset of
puberty. Many ofthese extrinsic factors are
not evenly distributed across ethnic and
socioeconomic populations and may con-
tribute to the observed decreased breast cancer
risk in Asian women (caloric restriction) and
increased risk for breast and uterine cancer
inAfricanAmerican women (obesityandearly
menarche). By definition, these extrinsic
factors would be considered epigenetic
contributors to increased risk.
Factors Affecting Tissue
Specificity
These factors can be broadly grouped into
those that modulate the transcriptional acti-
vation function ofsteroid hormone receptors
and those that occur as a result ofaltered pat-
terns of gene expression in specific tissues. A
new and important area ofinvestigation in
the former category is steroid hormone
receptor accessory proteins that can function
as either coactivators or corepressors for gene
transcription. Very little information is
presently available on how these proteins
might confer tissue-specific responsiveness,
and more research is needed on a) whether
polymorphisms in these accessory proteins
exist that might have functional conse-
quences for their activity, b) whether expres-
sion levels are different in different tissues
and how the ratio ofcoactivators to corepres-
sors affects receptor activation, and c) whether
tissue-specific modifications such as splicing
variants or phosphorylation might affect
their activity. These accessory proteins may
participate in nontraditional receptor activa-
tion pathways, which as mentioned above,
may be particularly sensitive to low-dose
exposures. SRC-1 can facilitate ligand-inde-
pendent activation ofsteroid hormone recep-
tors and in combination with NCoR can act
as a determinant of agonist or antagonist
activity for ligands such as tamoxifen (ER)
and RU486 (PR) and therefore, possibly for
endocrine disruptors aswell (22-24).
Tissue-specific receptor distribution or
number may also influence the response of
different tissues to endocrine disruptors (25).
ER-a and ER-f receptors exhibit tissue-
specific patterns ofexpression, with ovary,
prostate, testis, brain and bone being primar-
ily driven by ER-P (25). As ER-a and ER-f
have different agonist and antagonist activi-
ties for the same ligand, this expression pat-
tern could ultimately influence whether a
specific ligand acts as an agonist or antago-
nist in a given tissue (26). The mammary
gland also exhibits changes in ER and PR
expression as a function ofage and differenti-
ation status (for example, during pregnancy
or neonatal estrogen exposure) that can alter
its susceptibility to induction of breast
cancer; similar changes may occur in the
uterus as well (27). It should also be recog-
nized that there are numerous members of
the nuclear receptor family that are termed
orphan receptors because their ligands or
functions are unknown. However, it is evi-
dent from those ligands that have been iden-
tified that ligands are typically small
hydrophobic molecules. The identification of
orphan receptors that bind progesterone or
androgen metabolites suggests that some of
these receptors (e.g., the steroid and xenobi-
otic-sensing nuclear receptor) may also be
targets ofendocrine disruptors (28). Further
research to determine ifthese orphan recep-
tors contribute to the adverse health effects
ofendocrine disruptors will be needed.
Alongsimilarlines, it has been shown that
the activity ofa given receptor can have quite
different effects in different tissues and in dif-
ferent species. An example ofthis would be
endometrium and breast, where estrogen
priming (or possibly low-dose endocrine dis-
ruptor exposure) followed by progesterone
results in a mitogenic stimulus, whereas in
the ovary, progesterone induces an apoptotic
response. Species-specific behavioral responses
mediated by the PR have been observed at
the level ofthe brain. In rodents for example,
estrogen priming followed by progesterone
(Pg) is required for behavioral sexual estrus,
whereas in primates, expression ofsexual
behavior is inhibitedbyPg.
Differential gene expression in various
target tissues should also be considered as a
determinant oftissue-specific response (12).
Extrahepatic estrogen-metabolizing enzymes
display tissue-specific patterns ofexpression
resulting in different profiles or activity of
endogenous hormones in different tissues.
Exposure to endocrine disruptors that impact
the activity of these metabolizing enzymes
could therefore exhibit a tissue-specific target
cell pattern. Another example of tissue-
specific protein expression affecting response
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is metallothionine expression in the testis,
where expression ofthis protein is very low.
As a result ofthis low expression level, the
testis displays an increased sensitivity to Cd
that results from a cascade ofevents initiated
by decreased blood supply to this tissue,
decreased viability ofLeydig cells, and ulti-
mately decreased production oftestosterone.
Membrane-bound receptors for steroid hor-
mones are also differentially expressed and are
found primarily on sperm and neurons.
These receptors could potentially mediate
endocrine disruptor activity in these cells,
although research addressing this point is
lacking. Finally, the testis is another site of
SBP expression in addition to the liver, where
it is known as androgen-binding protein
(ABP). Here it primarily binds testosterone
and, in contrast to the production ofSBP in
the liver, is synthesized in both rat and
human testis. Different effects ofxenobiotics
have been observed on the binding of 5oc-
DHT to rat ABP or to human sex hormone-
binding globulin (29).
The immune system is another potentially
important but understudied target tissue for
endocrine disruptors. There is now a large
body ofliterature supporting the concept that
estrogens are potent immunomodulators.
Gender differences exist in both normal phys-
iology ofthe immune system as well as the
elaboration ofdiverse autoimmune diseases.
Furthermore, it is now clear that there are
bidirectional interactions between the
immune system, central nervous system, and
endocrine system. For example, castration of
males results in marked hyperplasia of the
thymus, whereas administration ofestrogens
or androgens induces thymic atrophy.
Conversely, neonatal thymectomy has been
shown to result in ovarian dysgenesis, auto-
immune oophenitis, and autoimmune thy-
roiditis. Given the fact that estrogen and
progesterone modulate inflammatory activity
in the mouse uterus (30), it is plausible that
xenoestrogens and other endocrine disruptors
that affect the endocrine system will likely
impact the immune system aswell.
Tissue-specific differences in response to
steroid hormones underscore the fact that
endocrine disruptors may use multiple cellular
mechanisms to produce an adverse cellular
response, and these mechanisms may be dif-
ferent at low- versus high-dose exposures.
Examples ofthis would be high- versus low-
dose effects of genistein, which has been
shown to have agonist effects mediated via the
ERbut can also have growth inhibitory effects
that are not receptor mediated, such as inhibi-
tion ofprotein tyrosine kinase activity at high
concentrations ofthis compound (31). Thus
itwill be important to achieve an understand-
ing ofthese and other tissue-specific determi-
nants ofresponsiveness to various endocrine
disruptors and to identify which pathways are
used at different dose levels.
Utility ofAvailable Model
Systems
Short-term in vitro assays that utilize reporter
genes may be useful tools for determining
a) the functional consequences of receptor
polymorphisms, interactions, and number;
b) the functional impact ofpolymorphisms in
metabolic enzymes; and c) the dose-response
relationships between promoter structure and
gene expression. The development of in vitro
assays that can address these questions would
be particularly useful for studying how these
parameters affect response to low doses of
endocrine disruptors, and should be a research
priority. Such assays may also prove useful for
assigning functionality to gene polymor-
phisms identified through the Environmental
Genome Project, which might impact
responsiveness to endocrine disruptors.
Several in vitro and in vivo model systems
that focus primarily on cellular responses
such as cell proliferation are currently avail-
able and these may also be useful for study-
ing the effects of endocrine disruptors on
susceptible populations. Breast cell lines from
individuals with inherited cancer susceptibili-
ties such as Li-Fraumeni syndrome (p53) and
BRCA1 mutations are available that display
differential responsiveness to chemical car-
cinogens. These cell lines may be useful for
studying the impact of low-dose exposures
on susceptible populations at increased risk
for adverse effects of endocrine disruptors
due to inherited mutations in relevant target
genes. However, the use ofboth short-term
assays and cell lines will have limited utility
for extrapolating how these susceptibility fac-
tors contribute to the variability observed in
heterogeneous human populations and for
understanding the biologic basis ofadverse
health effects observed in individuals exposed
to endocrine disruptors.
In this regard, in vivo models of cancer
susceptibility with relevance to adverse
health effects of endocrine disruptors are
also available and may be used to address
some of these questions. These include the
Noble rat for prostate and breast cancer,
Sprague-Dawley rat for breast cancer, F344
rat for pituitary tumors, and the Eker rat
model for uterine fibroids (32-35). These
models have been well characterized for their
sensitivity to steroid hormones, and research
opportunities exist for investigating the effects
ofendocrine disruptors on the specific target
tissues that are susceptible to endocrine mod-
ulation in these animal models. Some mouse
models are also available that may be useful
for this purpose, such as the T-ramp murine
prostatic carcinoma model and the mouse
mammary tumor virus (MMTV)-aromatase
transgenic mouse model for breast and
testicular cancer. The sensitivity of these
models to hormone-induced tumor develop-
ment may make them particularly useful for
studyinglow-dose effects ofendocrine disrup-
tors. More research in this area is recom-
mended. In particular, these in vivo models
may provide additional dosimetry data that
could be useful for modeling low-dose expo-
sures to these compounds.
An additional area for consideration of
model development is one or more behavioral
tests for endocrine disruptors. Alterations in
behavior are the outcome of a cascade of
effects at the molecular, cellular, and organ
levels. This is both a blessing in that it sums
across many effects and a curse in that it is
hard to attribute changes to specific internal
effects. Another issue to be addressed in the
development ofbehavioral models would be
when one considers the behavioral alteration
to be adverse. This topic may be more suit-
able to a small workshop of its own rather
than aworkshop on aspecific model.
Incorporation ofThis
Information into Improved
Risk Assessments
Three paradigms for translating relevant
information from the discussion above into
risk assessments for sensitive populations were
discussed: a) the use ofquantitative informa-
tion related to a receptor polymorphism that
affects receptor activity, b) use ofmechanistic
information to identify the critical rate-limit-
ing step for a model ofendocrine disruption,
and c) use ofa quantitative structure-activity
relationship (QSAR) approach for modeling
the activityofendocrine disruptors.
The example ofAR polymorphisms asso-
ciated with increased risk for prostatic cancer
was discussed as an example ofhow this type
ofinformation would be incorporated into a
risk assessment model. Decreases in the
polyglutamine repeat length in this receptor
are associated with increased cancer risk, with
loss ofeach repeat contributing an additional
3% increase in relative risk. Mechanistic data
suggest that the Kj ofthese receptor variants
is unchanged but that transactivation func-
tion ofthe receptor is functionally different.
Information needed for modeling this poly-
morphism could be acquired byestablishing a
quantitative dose-response relationship for
these receptor variants (Figure 1) to deter-
mine iftransactivation activity by these vari-
ants differed in sensitivity or responsiveness
to an endocrine disruptor and the magnitude
of these changes. This information could
then be translated to a population in which
these receptor variants were distributedwith a
given frequency to model the effect ofthese
polymorphisms on the response of an
exposed population.
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Figure 1. Generation of dose-response information for modeling the impact of receptor variants in terms of differ-
ences in their sensitivity (A) or responsiveness (B) to endocrine disruptors.
As part of these discussions it was also
noted that some important biologic responses
occurring as a result ofendocrine disruptor
exposure, particularly those that are qualita-
tive in nature, cannot be predicted by quan-
titative models. In many of these cases,
empirical observations related to the impact
ofcritical species or tissue-specific factors as
the underlying causes of divergent biologic
responses to endocrine modulation will be
required to recognize these phenomena. Two
examples illustrate this point. For breast
cancer development, the relevant target-cell
population are the terminal end buds (TEB)
(rat) or type I lobules (human), and quanti-
tating the number ofsuch end buds or lob-
ules exposed to carcinogens or endocrine
disruptors can model cancer risk. However,
as discussed above, the response ofthese cells
to steroid hormones or endocrine disruptors
is different at different stages of develop-
ment. Thus, data on the ability ofestrogenic
compounds to promote tumor development
would not have predicted the observation
that perinatal exposure to genistein is protec-
tive for mammary carcinogenesis. This pro-
tective effect is due to the induction of
differentiation of the TEB in the mammary
epithelium to a more mature differentiated
state that is refractive to tumor induction
(36). This emphasizes the importance of
considering windows of susceptibility and
the mechanistic basis responsible for differ-
ential susceptibility (in this case, stage of life
cycle) in modeling the activity of endocrine
disruptors. Similar examples can be described
for species-specific determinants ofvariabil-
ity. For example, in rats, perinatal exposures
to low-dose estrogens results in decreased
prostate weight in the adult and a decrease in
testis size (37). In contrast, in the mouse, a
similar perinatal exposure produces an
increase in the size ofthe adult prostate (38).
This illustrates how qualitative species-
specific determinants ofsusceptibility must
be recognized and incorporated into risk
assessment models.
However, once these qualitative
differences have been elucidated, this mecha-
nistic understanding ofthe biologic basis for
the observed effect may then be incorporated
into a risk assessment model. This involves
identification ofthe rate-limiting step in this
process and constructing a dose-response
relationship that can describe this process.
For instance, in the above example, the
decrease in prostate size is a result of dis-
rupted tissue architecture caused by estrogen
exposure in the prostate. Normally in the rat,
during the early postnatal period a testos-
terone surge occurs that determines prostate
architecture. The presence of estrogens dur-
ing this critical period of development
interferes with this surge, impairing the devel-
opment ofthe prostate. The identification of
this as the rate-limiting step for the activity
of exogenous estrogens focuses the quantita-
tion on the impact of dose of estrogen (or
endocrine disruptor) on testosterone levels.
This quantitative information can then be
incorporated into a biologically based model
to predict the response of this tissue to
exogenous estrogen exposure during the
perinatal period (Figure 2).
Finally, a QSAR approach to modeling
the behavior ofendocrine disruptors was rec-
ognized as beingvaluable in terms ofincorpo-
rating molecular or biologic factors that act as
determinants ofsusceptibility or variation in
the population (39). For instance, several
receptor properties related to receptor-ligand
interactions that were discussed above could
produce shifts in the dose-response curve. An
example ofsuch a factor would be differences
in the affinity ofsteroid hormone receptors
for a given ligand. For example ER-a and
ER-, bind xenoestrogens with different
affinities. If these receptors were present in
different ratios in different cell types, the
response of these cells to the same ligand
could be quantitatively different. Similarly,
differences between the off-rates ofER lig-
ands such as zeralonol or estrogen metabolites
relative to estradiol could also shift the
dose-response curve and have an impact at
low-dose exposures.
Conclusion
Understanding the biologic and molecular
basis ofspecies, interindividual, and tissue-
specific effects ofendocrine-active agents will
be critical for predicting responses at these
different levels. The potential adverse health
impact of low-dose exposure to endocrine-
active agents will vary between individuals
and between different target tissues, and our
ability to extrapolate data relevant to human
health from studies in animal model systems
will require an improved understanding of
species-specific determinants of response.
Additional research will be needed to eluci-
date how patterns of gene expression in
response to endocrine-active compounds dif-
fer across species and how polymorphisms at
the receptor level and in hormone-metaboliz-
ing genes influence individual response to
endocrine-active compounds. More informa-
tion is also needed on how expression of
receptor accessory proteins such as coactiva-
tors and corepressors differs between tissues
and the functional consequences these
expression patterns may have on receptor
activity. Orphan receptors may also interact
with endocrine-active agents, and additional
research is needed to determine if these
receptors contribute to the adverse health
impact ofendocrine disruptors. The develop-
ment ofnew in vitro and animal models will
be crucial for advancing our understanding of
the effects ofthese and other determinants of
specificity yet to be identified. Equally
important will be the development of
mathematical models that can be used to
incorporate information on species, interindi-
vidual, and tissue-specific determinants in
order to accurately predict adverse health
outcomes at low-dose exposures.
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Figure 2. Quantitation of the impact of xenoestrogens
on effective testosterone levels and subsequent impact
on prostate development.
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